 -Kirk Tjalas, F.N.P.
Kirk Tjalas, F.N.P., provides exceptional care and meticulous attention to detail for every patient concern, ensuring comprehensive and personalized treatment for optimal health outcomes. |
More than 10 million Americans were taking GLP-1 medications in 2025 ,a number projected to reach 25 million by 2030. Originally approved to treat type 2 diabetes, drugs like semaglutide (Ozempic, Wegovy) and liraglutide have since become household names for weight loss. But here’s something most patients don’t hear about at their first prescription appointment: GLP-1 medications and mental health are increasingly, and fascinatingly, intertwined.
A landmark study published in Lancet Psychiatry in early 2026 found that semaglutide use was linked to a 42% decreased risk of worsening mental health outcomes ,including a 44% lower risk of worsening depression and a 38% reduction in worsening anxiety. At the same time, the picture isn’t entirely rosy, and experts urge patients not to view these drugs as a mental health cure-all. If you or someone you love is considering or already taking a GLP-1 medication, here’s what the science actually says ,and what it doesn’t.
How GLP-1 Medications Work in the Brain
Most people think of GLP-1 receptor agonists as gut drugs ,they slow digestion, reduce appetite, and regulate blood sugar. But GLP-1 receptors aren’t just found in your stomach and pancreas. They exist throughout your central nervous system, including in the hypothalamus, hindbrain, and amygdala ,brain regions tied to mood regulation, stress response, and reward.
This is why the conversation about GLP-1 medications and mental health has taken off in research circles. When these medications activate GLP-1 receptors in the brain, they may:
- Reduce systemic inflammation, which is increasingly linked to depression
- Stimulate neurogenesis (the growth of new brain cells)
- Improve insulin signaling in the brain
- Influence the dopamine reward system, potentially reducing compulsive behaviors
A 2025 analysis in Nature Mental Health reviewed 278 preclinical and 96 clinical studies on GLP-1 medications and psychiatric conditions ,one of the most comprehensive reviews to date. The findings suggest real neurobiological mechanisms behind the mood benefits some patients report, though researchers emphasize the science is still evolving.
The Mental Health Benefits: What the Research Shows
Let’s look at what the data actually supports when it comes to GLP-1 medications and mental health outcomes.
Depression: A large Swedish study tracking nearly 100,000 individuals found that semaglutide users experienced a 44% reduction in worsening depression compared to periods when they weren’t using the drug. Liraglutide showed a more modest but still significant 26% reduction. Importantly, psychiatric hospital visits dropped by 42% during periods of semaglutide use.
Anxiety: A nationwide cohort study found that GLP-1 medications reduced cumulative anxiety incidence by 2.13% compared to non-users. The effect was most pronounced in women and in people aged 40 to 60. Notably, the benefits grew stronger the longer patients stayed on treatment ,with significant improvements appearing after six or more months of consistent use.
Substance Use Disorders: Perhaps the most surprising finding: semaglutide was linked to a 47% reduced risk of worsening substance use disorders, including alcohol. Researchers believe the drug’s influence on the brain’s dopamine reward circuitry may dampen addictive urges ,a finding now being explored in clinical trials for alcohol use disorder.
Suicide and Self-Harm: As a group, GLP-1 medications were associated with a 44% reduced risk of self-harm in the Lancet Psychiatry study. This is particularly meaningful given that people with obesity and diabetes already face elevated baseline rates of depression and suicide risk.
If you’re already managing conditions like panic disorder, PTSD, or seasonal affective disorder, understanding how GLP-1 medications and mental health intersect could be an important part of your care conversation.
The Risks and Unknowns You Need to Know
The relationship between GLP-1 medications and mental health is not one-sided. Early clinical trials for Wegovy and Zepbound actually excluded individuals with depression or prior suicidal thoughts, meaning the research base for these populations was thin from the start. And while more recent real-world studies are filling in those gaps, significant questions remain.
Mood changes can go either way. Social media reports and observational studies document cases where people experienced worsening anxiety, insomnia, or low mood after starting GLP-1 therapy. Individual brain chemistry, baseline mental health status, and expectations about weight loss all appear to influence outcomes.
Unmet expectations are a real risk. For patients who hope GLP-1 medications will solve emotional eating, body image struggles, or depression tied to weight, the results can be disappointing ,and in some cases, destabilizing. Weight loss alone rarely addresses the underlying psychology of disordered eating or emotional dysregulation.
Eating disorders deserve special attention. As explored in a February 2026 NPR report, the rise in GLP-1 prescriptions through telehealth platforms with minimal mental health screening has raised alarms. People with restrictive eating disorders may use these drugs in dangerous ways, and the drugs’ appetite-suppressing power can intensify disordered behaviors. This is especially relevant given what we know about emotional dysregulation and disordered eating patterns.
Who May Benefit Most ,and Who Should Use Caution
Not everyone on a GLP-1 medication will notice mental health changes. The research points to some groups that may see more significant effects from GLP-1 medications and mental health outcomes:
Likely to benefit:
- Adults aged 40–60 with anxiety or depression related to metabolic conditions
- Women (the research shows stronger anxiety-reduction effects in female patients)
- People with obesity-related depression or low self-esteem linked to body weight
- Those with alcohol use disorder (emerging evidence, still under study)
Use extra caution if you have:
- Active eating disorders, including anorexia or binge-eating disorder
- Bipolar disorder or psychotic conditions (very limited research exists here)
- Suicidal ideation ,though GLP-1s appear linked to lower self-harm risk, they are not psychiatric treatments and should never replace established mental health care
If you’re in the perimenopause phase of life, where hormonal shifts already affect mood and metabolism, you may want to read more about how perimenopause interacts with mental health and weight changes before starting a GLP-1 medication.
What to Tell Your Doctor Before Starting
Transparency with your provider is everything. The relationship between GLP-1 medications and mental health is nuanced enough that a one-size-fits-all approach won’t serve you. Before starting ,or adjusting ,a GLP-1 medication, consider sharing:
- Any current or past mental health diagnoses, especially mood disorders, anxiety, or eating disorders
- Your history with substances, including alcohol
- Medications you currently take for mental health (some have metabolic interactions)
- Your realistic expectations around weight loss and how you might respond if results are slower than hoped
And if you’re already on a GLP-1 drug, don’t dismiss mood changes as unrelated. Whether you feel noticeably better ,or unexpectedly worse ,your prescribing provider needs to know. Whole-person care means treating the mind and body as the connected system they are.
For those navigating the weight loss medication landscape, our post on oral Wegovy vs. injectable options can help clarify which form might be right for you.
Practical Steps You Can Take Right Now
Understanding the connection between GLP-1 medications and mental health is the first step. Here’s how to move forward thoughtfully:
- Schedule a comprehensive intake conversation with your provider that includes a mental health history ,not just weight and blood sugar metrics.
- Track your mood for the first 3–6 months on any GLP-1 medication. Patterns matter more than single days.
- Don’t wait for a crisis. If you notice worsening anxiety, depression, or disordered eating behaviors, reach out before symptoms escalate. Our guide on preventive mental health care explains why early intervention is almost always better.
- Ask about behavioral support. The WHO’s 2025 guideline on GLP-1 therapies recommends pairing medication with structured dietary and lifestyle interventions ,and the same logic applies to mental health support.
- Be honest about your relationship with food. Appetite suppression from GLP-1s can mask ,or worsen ,disordered eating patterns. A therapist or dietitian who understands both metabolic health and mental health can be an invaluable partner.
A New Frontier That Demands Whole-Person Thinking
The research on GLP-1 medications and mental health is genuinely exciting. The possibility that a drug targeting blood sugar and weight might also ease depression, anxiety, and even addictive behaviors reflects how deeply connected our metabolic and mental lives truly are. But excitement shouldn’t outpace caution.
These medications aren’t psychiatric drugs. They work differently with different people. And the populations most vulnerable to mental health complications ,those with eating disorders, complex mood conditions, or unrealistic expectations ,are often the least screened before a prescription is written.
At Priority Medical Group, our approach to GLP-1 medications and mental health is grounded in whole-person care: that means asking questions about your mental health at every stage, not just checking a box and sending you home with a prescription. If you’re navigating these decisions, you don’t have to do it alone.
Ready to explore whether a GLP-1 medication is right for you ,body and mind? Talk to our team at pmgcare.com.
FAQ:
| 1. Can GLP-1 medications treat depression or anxiety directly? | No ,GLP-1 medications like semaglutide and liraglutide are not approved psychiatric treatments. However, emerging research suggests they may reduce the risk of worsening depression and anxiety in people who already have these conditions. They should never replace therapy or prescribed psychiatric medications. |
| 2. How long does it take to notice mental health changes on a GLP-1 medication? | Studies suggest the mental health benefits tend to grow over time. Research found significant risk reductions in anxiety and depression appearing after six or more months of continuous use. Individual timelines vary based on starting health status, weight changes, and other factors. |
| 3. Is it safe to take a GLP-1 medication if I already take an antidepressant? | Many people take GLP-1 medications alongside antidepressants without issue, but there are important interactions to discuss. Nausea ,one of the most common GLP-1 side effects ,can affect how consistently you absorb oral medications. Always disclose your full medication list to your prescriber. |
| 4. Can GLP-1 medications make mental health worse? | Yes, for some people. While many studies show mental health improvements, individual responses vary. People with eating disorders, body dysmorphia, or those who don’t meet their weight loss expectations may experience worsening mood or anxiety. Ongoing monitoring by a healthcare provider is essential. |
| 5. Why were people with depression excluded from early GLP-1 clinical trials? | The pivotal trials for Wegovy and Zepbound excluded individuals with depression or prior suicidal ideation as a safety precaution ,the drugs were new and researchers didn’t yet understand their neuropsychiatric effects. This created a significant evidence gap that newer real-world studies are now working to fill. |
| 6. Are men and women affected differently by GLP-1 medications on mental health? | Research suggests the anxiety-reducing effects of GLP-1 medications appear stronger in women than in men, and are most pronounced in the 40–60 age range. The reasons aren’t fully understood but may relate to hormonal differences and variations in how GLP-1 receptors function across sexes. |
SEE MORE HERE“Experience exceptional care with Kirk Tjalas, F.N.P. Book your appointment now and take charge of your health with confidence and badassery.”
|